Skip to content

Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes

Barriers and Facilitators to Exercise for Individuals With Autoimmune Myasthenia Gravis, Congenital Myasthenic Syndrome or Lambert-Eaton Myasthenic Syndrome in France: a Descriptive, Cross-sectional Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05408702
Acronym
MYaEX
Enrollment
500
Registered
2022-06-07
Start date
2021-11-12
Completion date
2022-05-15
Last updated
2022-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Myasthenia Gravis, Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Myasthenia Gravis

Brief summary

A few recent observational studies show that despite the lack of clear recommendations, many individuals with myasthenia participate in exercise. However, no link has been found between exercise and the severity of myasthenia symptoms, measured by the Muscle Myasthenia Score or the Myasthenia Gravis Composite Score. This suggests that there are other factors that may limit or prevent some individuals from being active, or factors which may facilitate participation in exercise. Studies in other diseases have shown that there are internal (beliefs, motivation, etc.) and external (cost, accessibility, etc.) factors unrelated to the disease which may play a role in exercise participation. The aim of this study is to identify factors that facilitate or limit exercise in individuals with autoimmune myasthenia gravis, congenital myasthenia syndrome and Lambert-Eaton syndrome.

Interventions

None listed

Sponsors

Association Française contre les Myopathies (AFM), Paris
CollaboratorOTHER
Institut de Myologie, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* at least 18 years old * confirmed diagnosis of MG or SMC or LEMS * Live in France or its territories * Provide consent

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Barriers and facilitators to exerciseSix months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026